<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The immunomagnetic <z:mpath ids='MPATH_63'>depletion</z:mpath> method for removing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells from bone marrow, previously refined using a Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> model, was tested with <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>The efficiency of <z:mpath ids='MPATH_63'>depletion</z:mpath> was quantified by immunofluorescence with a detection limit of 3.3 log of cell <z:mpath ids='MPATH_63'>depletion</z:mpath> corresponding to the elimination of 99.84% of an initial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell content of 10% </plain></SENT>
<SENT sid="2" pm="."><plain>A panel of five monoclonal antibodies (UJ13A; UJ127.11; UJ181.4; alpha-Thy1; H11) purged 2.8 log of SKNBE and LAN-1 cells, while two of these antibodies as single agents allowed only for a 1.7 log (UJ13A) and a 1.7 to 2.0 log (alpha-Thy1) <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>This underlines the advantage of an antibody panel for <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> purging </plain></SENT>
<SENT sid="4" pm="."><plain>The new antibody S-L 11.14, an IgG2a against <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e> which recognizes 90% of <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> cells purged 2.8 log </plain></SENT>
</text></document>